Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for hematologic malignancies, yet its efficacy in solid tumors remains limited by poor persistence, T-cell exhaustion, and an immunosuppressive tumor microenvironment (TME). To address these barriers, “cytokine armored” CAR-T cells, also known as fourth-generation CAR-T or TRUCKs, have been developed. These cells are engineered to produce or respond to cytokines that enhance their function, reshape the TME, and recruit endogenous immunity.
This report outlines the major cytokine armoring strategies, the cytokines being used, their biological rationale, and how molecular design influences CAR-T efficacy in cancer.
Cytokine Armoring Strategies
Cytokine armoring of CAR-T cells represents a rational extension of adoptive T-cell engineering in which additional genetic cassettes are introduced to augment canonical CAR signaling with engineered cytokine biology. Rather than relying solely on antigen-driven CD3ζ and costimulatory signaling, these systems incorporate cytokine programming to provide autocrine trophic support, establish paracrine immunomodulatory effects within the tumor microenvironment (TME), and enhance resistance to extrinsic inhibitory cues such as TGF-β, IL-10, and myeloid-derived suppressor cell–mediated suppression. At a systems level, cytokine armoring effectively converts CAR-T cells from purely cytolytic effectors into multifunctional immune regulatory nodes capable of actively reshaping local immune ecology.
TRUCKs (Inducible Cytokine Expression)
T cells Redirected for Universal Cytokine-mediated Killing (TRUCKs) represent a first principle approach to coupling antigen recognition with spatially restricted cytokine delivery. In these systems, cytokine transgene expression is placed under the control of activation-dependent transcriptional programs, most commonly NFAT-responsive promoters downstream of CAR-mediated CD3ζ signaling. Upon antigen engagement and immunological synapse formation, calcium-dependent calcineurin activation leads to NFAT nuclear translocation and subsequent transcriptional induction of cytokine genes such as IL-12, IL-18, or IL-15. This design ensures that cytokine secretion is tightly confined to sites of antigen recognition, thereby limiting systemic exposure and reducing on-target off-tumor toxicities. Functionally, TRUCKs not only reinforce autocrine CAR-T activation through JAK/STAT and NF-κB pathway engagement but also exert potent paracrine effects, recruiting and activating innate immune cells including dendritic cells, macrophages, and NK cells, thereby amplifying local antitumor immunity beyond the engineered T-cell population.
Constitutive Secretion
In contrast to inducible systems, constitutive cytokine secretion strategies employ strong, continuously active promoters to drive persistent cytokine expression independent of antigen stimulation. This results in sustained cytokine exposure within both autocrine and microenvironmental contexts, leading to chronic activation of downstream signaling cascades such as JAK/STAT5, PI3K/AKT, and mTOR. The functional consequence is enhanced CAR-T cell proliferation, survival, and differentiation toward long-lived effector or memory phenotypes, which can significantly improve persistence in vivo. However, constitutive signaling inherently lacks spatial restriction, which increases the risk of systemic cytokine dissemination, contributing to cytokine release syndrome, neurotoxicity, and off-tumor immune activation. Thus, while constitutive secretion can maximize CAR-T potency, it introduces a narrow therapeutic window that must be carefully balanced against toxicity.
Membrane-bound Cytokines
Membrane-bound cytokine engineering involves the tethering of cytokine ligands to the CAR-T cell surface through transmembrane domains or scaffold proteins, exemplified by membrane-bound IL-15 constructs. This configuration restricts cytokine activity to juxtacrine signaling between CAR-T cells and adjacent immune cells, thereby eliminating systemic diffusion while preserving potent receptor engagement. Functionally, this promotes enhanced CAR-T cell survival, metabolic fitness, and resistance to activation-induced apoptosis while minimizing systemic toxicity.
Chimeric Cytokine Receptors
Chimeric cytokine receptors represent a form of signal rewiring in which extracellular domains of inhibitory cytokine receptors are fused to intracellular signaling domains from stimulatory receptors. This allows suppressive cytokines within the tumor microenvironment, such as IL-4 or TGF-β, to be converted into pro-survival and pro-proliferative signals. Upon ligand binding, these engineered receptors bypass native inhibitory signaling pathways (such as SMAD-mediated transcription downstream of TGF-β) and instead activate alternative cascades, most commonly STAT5-driven transcriptional programs associated with T-cell expansion and effector differentiation. Functionally, this design enables CAR-T cells to not only resist immunosuppressive cues but to actively exploit them as activation signals, thereby converting a hostile tumor microenvironment into a permissive or even stimulatory niche for T-cell activity.
Collectively, cytokine armoring strategies are designed to address the principal limitations of first-generation CAR-T cells by enhancing in vivo expansion and persistence, increasing cytolytic potency, promoting durable memory formation, remodeling immunosuppressive tumor microenvironments, and enabling recruitment of endogenous immunity to mitigate antigen heterogeneity. At a mechanistic level, these approaches fundamentally expand CAR-T cell biology from antigen-restricted cytotoxicity to integrated immune system engineering, in which engineered lymphocytes function as localized cytokine delivery platforms and immune ecosystem modulators.
Cytokine Armory
Different cytokines used in CAR-T cell armoring are strategically selected to modulate distinct aspects of T-cell biology and the tumor microenvironment. Collectively, these cytokines operate through complementary mechanisms, including enhancement of T-cell persistence (IL-15, IL-7), amplification of effector function and inflammation (IL-12, IL-18), optimization of metabolic fitness (IL-21), and recruitment of additional immune populations (CCL19). Emerging cytokines further expand this toolkit, enabling more precise tuning of immune responses. Together, these approaches illustrate a shift toward multifunctional CAR-T systems that integrate intrinsic fitness with extrinsic immune modulation to improve therapeutic efficacy, particularly in challenging solid tumor settings.
Key Cytokines Used in Armored CAR-T Cells and Their Biological Rationale
| Cytokine / Strategy | Mechanism | Biological Rationale | Functional Effect | Key Considerations |
| IL-12 (Pro-inflammatory TME reprogramming) | Activates T cells, NK cells, and dendritic cells via STAT4 signaling; induces high IFN-γ production and enhanced cytotoxicity | Converts immunologically “cold” tumors into inflamed, immune-permissive environments | Enhances cytotoxicity, promotes antigen spreading, and recruits innate immune effectors | Potent efficacy but associated with systemic toxicity if not tightly regulated |
| IL-15 (Survival and persistence) | Signals through IL-15Rα/IL-2Rβ/γc complex to activate STAT5, PI3K/AKT, and MAPK pathways; promotes memory T-cell differentiation | Addresses limited in vivo persistence and poor expansion of CAR-T cells | Sustained proliferation, enhanced stem-like phenotype, improved long-term persistence | Strong driver of expansion and durability; may increase risk of cytokine-related toxicity |
| IL-18 (Innate–adaptive immune bridging) | Induces NF-κB and IFN-γ; stimulates macrophages, NK cells, and endogenous T cells | Broadens immune response beyond CAR specificity by engaging host immunity | Enhances expansion, persistence, and bystander immune activation | Effective in refractory settings but may drive systemic inflammation |
| IL-7 + CCL19 (Trafficking and immune recruitment) | IL-7 promotes survival via STAT5; CCL19 recruits CCR7+ T cells and dendritic cells, enhancing immune cell trafficking | Improves tumor infiltration and coordination of adaptive immune responses | Increased tumor homing, immune cell recruitment, and formation of lymphoid-like structures | Enhances infiltration and resistance to lymphodepletion; supports multi-cellular immune responses |
| IL-21 (Metabolic fitness and reduced exhaustion) | Activates STAT3 signaling; maintains oxidative metabolism and limits terminal differentiation | Prevents exhaustion and dysfunction associated with chronic stimulation | Sustained effector function, reduced senescence, improved long-term activity | Supports durable functionality with lower exhaustion compared to IL-2/IL-12 |
| Emerging Cytokines (IL-36γ, IL-23, IL-2 variants) | IL-36γ activates APCs and NF-κB pathways; IL-23 supports Th17 responses; IL-2 variants selectively engage receptor subunits | Expands functional diversity of CAR-T modulation and fine-tunes immune responses | Enhanced immune amplification, sustained inflammatory responses, or reduced toxicity (engineered IL-2) | Early-stage approaches with potential for improved specificity and safety |
Functional Impact on CAR-T Efficacy
Cytokine armoring fundamentally reshapes CAR-T cell performance by integrating intrinsic T-cell fitness programs with extrinsic modulation of the tumor microenvironment, thereby enhancing therapeutic efficacy across multiple, interdependent biological dimensions.
Persistence and Expansion
The incorporation of homeostatic cytokines such as IL-15 and IL-7 into CAR-T platforms directly influences T-cell survival, proliferative capacity, and differentiation state through sustained activation of JAK/STAT5 signaling pathways. These cytokines promote the maintenance of central memory and stem cell–like memory phenotypes, characterized by high proliferative potential, metabolic adaptability, and resistance to terminal differentiation. IL-15 supports mitochondrial integrity and oxidative phosphorylation, while IL-7 enhances survival through upregulation of anti-apoptotic proteins such as BCL-2. Collectively, these effects enable prolonged in vivo persistence and sustained clonal expansion following antigen encounter, which are critical determinants of durable tumor control and long-term remission.
Cytotoxicity
Pro-inflammatory cytokines such as IL-12 and IL-18 significantly augment the cytolytic capacity of CAR-T cells by amplifying canonical effector signaling pathways. These cytokines enhance the production of IFN-γ and TNF-α through activation of STAT4- and NF-κB-dependent transcriptional programs, thereby reinforcing Th1 polarization and effector differentiation. At the cellular level, this results in increased expression and release of cytotoxic mediators, including perforin and granzymes, as well as upregulation of death receptor ligands such as FasL and TRAIL. In addition, IL-12 and IL-18 can potentiate bystander immune activation, further amplifying tumor cell killing through recruitment and activation of NK cells and macrophages. The net effect is a marked enhancement of both direct CAR-mediated cytotoxicity and indirect immune-mediated tumor clearance.
Tumor Microenvironment Remodeling
Cytokine-armored CAR-T cells exert profound effects on the tumor microenvironment by shifting it from an immunosuppressive to an immunostimulatory state. Pro-inflammatory cytokines such as IL-12, IL-18, and IFN-γ disrupt suppressive signaling networks mediated by regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. These cytokines promote polarization of macrophages toward an M1-like phenotype, enhance antigen presentation through upregulation of MHC class I and II molecules, and stimulate dendritic cell maturation and cross-priming capacity. Additionally, they can inhibit angiogenesis and alter stromal composition, thereby improving immune accessibility. This coordinated remodeling facilitates the establishment of a pro-inflammatory niche that supports sustained immune activation and epitope spreading, ultimately broadening the antitumor response beyond the initial CAR target.
Trafficking and Infiltration
Effective tumor eradication by immune cells requires efficient trafficking to and infiltration within tumor sites, processes that are often limited in solid malignancies. Engineering CAR-T cells to co-express chemokines such as CCL19 enhances their ability to recruit CCR7-expressing immune cells, including naïve and central memory T cells as well as dendritic cells. This chemokine-driven recruitment promotes the formation of organized immune microstructures resembling tertiary lymphoid organs within tumors, facilitating local antigen presentation and amplification of adaptive immune responses. In parallel, cytokine-mediated upregulation of adhesion molecules and chemokine receptors further enhances CAR-T cell homing and retention within tumor tissue. These combined effects improve intratumoral accumulation and functional engagement of CAR-T cells.
Antigen Escape Prevention
One of the major limitations of conventional CAR-T therapy is tumor antigen heterogeneity and the emergence of antigen-negative escape variants. Cytokine armoring mitigates this challenge by promoting recruitment and activation of endogenous immune populations, thereby extending the antitumor response beyond single antigen specificity. Cytokines such as IL-12 and IL-18 enhance dendritic cell–mediated antigen presentation and cross-priming of host T cells against a broader repertoire of tumor-associated antigens. This process drives epitope spreading and generates a polyclonal immune response capable of targeting antigen-loss variants. Consequently, cytokine-armored CAR-T cells function not only as direct cytotoxic agents but also as initiators of a more comprehensive and adaptable antitumor immune response, reducing the likelihood of immune escape and improving overall therapeutic durability.
Cytokine-Armored CAR-T Cells in Clinical Trials
Cytokine armoring has emerged as one of the most clinically advanced strategies to enhance CAR-T cell efficacy, particularly in settings where conventional CAR-T therapies fail due to limited persistence, T-cell exhaustion, or immunosuppressive tumor microenvironments. Among the most actively investigated approaches in clinical trials are CAR-T cells engineered to express IL-15, IL-18, or inducible IL-12 (TRUCKs). These platforms represent distinct mechanistic paradigms: IL-15 primarily enhances T-cell intrinsic fitness, IL-18 amplifies both intrinsic and extrinsic immune responses, and IL-12 TRUCKs function as localized immune activators that reshape the tumor microenvironment. Together, they illustrate how cytokine biology can be leveraged to overcome key barriers in cancer immunotherapy.
IL-15 Armored CAR-T Cells
Clinical Development and Targets
- IL-15 armored CAR-T cells are among the most clinically advanced cytokine-engineered platforms, with multiple phase I trials evaluating their activity in both hematologic malignancies and solid tumors. A prominent example is glypican-3 (GPC3)-targeted CAR-T cells co-expressing IL-15 in hepatocellular carcinoma and other GPC3-positive tumors (1). In early clinical studies, IL-15 co-expression significantly improved CAR-T expansion and antitumor responses compared to non-armored counterparts, achieving measurable disease control and objective responses in patients with otherwise refractory disease. Additional trials are exploring IL-15 (often combined with IL-21) in pediatric and adult solid tumors, reflecting broad translational interest.
Molecular and Cellular Mechanisms
- IL-15 is a homeostatic γ-chain cytokine that signals through IL-15Rα in complex with IL-2/15Rβ and γc, activating STAT5, PI3K/AKT, and MAPK pathways. In CAR-T cells, ectopic IL-15 expression sustains autocrine and paracrine signaling that promotes survival, proliferation, and resistance to apoptosis. Importantly, IL-15 favors the maintenance of T_SCM and T_CM subsets, which exhibit enhanced self-renewal capacity and long-term persistence. At the metabolic level, IL-15 promotes mitochondrial fitness and oxidative phosphorylation, supporting sustained effector function under nutrient-limited tumor conditions.
Impact on Antitumor Activity
- Clinically, IL-15 armoring results in significantly increased in vivo expansion and persistence of CAR-T cells, which are key correlates of therapeutic efficacy. In solid tumors, where CAR-T persistence is typically poor, IL-15 enhances tumor infiltration and prolongs functional activity. However, increased cytokine signaling can also elevate the risk of cytokine release syndrome (CRS), necessitating incorporation of safety switches or cytokine modulation strategies in clinical designs.
IL-18 Armored CAR-T Cells
Clinical Development and Targets
- IL-18 armored CAR-T cells are currently being evaluated in multiple early-phase clinical trials targeting hematologic malignancies and solid tumors, including CD19+ lymphomas and CD371+ acute myeloid leukemia (2). One notable example is the huCART19-IL18 platform, which has demonstrated activity in patients who relapsed after prior CAR-T therapy. Additional trials have reported encouraging responses, including minimal residual disease–negative remissions in AML patients.
Molecular and Cellular Mechanisms
- IL-18 is a member of the IL-1 cytokine family and signals through IL-18Rα/β, leading to activation of MyD88-dependent pathways, NF-κB, and AP-1 transcriptional programs. In CAR-T cells, IL-18 acts both intrinsically and extrinsically. Autocrine signaling enhances CAR-T proliferation, IFN-γ production, and cytotoxic differentiation, while paracrine signaling recruits and activates NK cells, macrophages, and dendritic cells. This dual mode of action effectively broadens the immune response beyond CAR specificity.
Impact on Antitumor Activity
- Clinically, IL-18 armoring has been associated with improved tumor clearance, particularly in heavily pretreated or CAR-T–refractory patients. Mechanistically, IL-18 promotes epitope spreading and enhances endogenous immune activation, thereby reducing dependence on single antigen targeting. However, its potent pro-inflammatory activity also drives high levels of IFN-γ and systemic immune activation, contributing to CRS and dose-limiting toxicities in some patients. These findings highlight the need for regulated expression systems, such as inducible or NFAT-driven IL-18 constructs, to balance efficacy and safety.
IL-12 TRUCK CAR-T Cells
Clinical Development and Targets
- IL-12–secreting CAR-T cells, often referred to as TRUCKs (T cells Redirected for Universal Cytokine-mediated Killing), are being evaluated in early-phase clinical trials targeting both hematologic malignancies and solid tumors (3). For example, CD19-targeted CAR-T cells engineered to express IL-12 have entered phase I studies in relapsed or refractory B-cell malignancies. These approaches aim to exploit IL-12’s potent immunostimulatory properties while mitigating its known systemic toxicity through localized delivery.
Molecular and Cellular Mechanisms
- IL-12 signals through the IL-12 receptor complex (IL-12Rβ1/β2), activating STAT4 and driving robust Th1 polarization. In TRUCK designs, IL-12 expression is typically controlled by activation-dependent promoters such as NFAT, ensuring that cytokine release is restricted to sites of CAR engagement. Upon antigen recognition, CAR signaling induces IL-12 secretion, which enhances IFN-γ production, promotes cytotoxic differentiation, and activates innate immune cells including NK cells and macrophages.
Impact on Antitumor Activity
- The principal advantage of IL-12 TRUCKs lies in their ability to remodel the tumor microenvironment. IL-12 promotes dendritic cell maturation, enhances antigen presentation, and drives macrophage polarization toward pro-inflammatory phenotypes. This results in recruitment of endogenous immune responses and facilitates epitope spreading, thereby overcoming antigen heterogeneity. In solid tumors, where immune exclusion is a major barrier, IL-12-mediated inflammation can convert “cold” tumors into immunologically active sites. However, due to the well-documented systemic toxicity of IL-12, strict control of its expression remains critical for clinical translation.
IL-15, IL-18, and IL-12 TRUCK CAR-T cells represent three mechanistically distinct but complementary approaches to cytokine armoring currently being tested in clinical trials. IL-15 primarily enhances CAR-T persistence and metabolic fitness, IL-18 amplifies both intrinsic and extrinsic immune responses to broaden antitumor activity, and IL-12 TRUCKs function as localized immune activators that reprogram the tumor microenvironment. Clinical data to date demonstrate clear improvements in expansion, response rates, and activity in refractory disease settings, but also underscore the importance of balancing efficacy with cytokine-driven toxicity. Future iterations will likely incorporate inducible systems, safety switches, and combinatorial designs to further refine these platforms and expand their applicability, particularly in solid tumors where current CAR-T therapies remain limited.
Conclusion
In conclusion, cytokine-armored CAR-T cells represent a significant evolution in adoptive cell therapy, addressing many of the limitations associated with first-generation CAR-T approaches, particularly in the context of solid tumors. By incorporating cytokine armoring strategies, such as the constitutive or inducible expression of IL-12, IL-15, IL-18, and other immunomodulatory factors, these engineered cells can actively reshape the tumor microenvironment, enhancing immune infiltration, overcoming immunosuppressive signaling, and promoting sustained antitumor activity. At the cellular level, cytokine armoring improves CAR-T cell proliferation, persistence, and resistance to exhaustion, while at the therapeutic level it translates into more durable responses, improved tumor clearance, and the potential to convert immunologically “cold” tumors into responsive ones.
Recent clinical trials evaluating cytokine-armored CAR-T cells have provided early evidence of safety and promising efficacy, demonstrating that these next-generation constructs can be administered with manageable toxicity profiles while achieving meaningful clinical responses in both hematologic malignancies and solid tumors. These studies also underscore the importance of carefully balancing cytokine potency with safety, as excessive cytokine activity may increase the risk of systemic inflammation or cytokine release syndrome. Looking forward, continued refinement of cytokine expression systems, including tunable, localized, or tumor-inducible platforms, will be critical for maximizing therapeutic benefit while minimizing adverse effects. Future directions will likely involve integration with additional engineering strategies, such as logic-gated CAR designs, combination therapies with checkpoint inhibitors, and personalized approaches guided by tumor-specific biomarkers. Collectively, these advances position cytokine-armored CAR-T cells as a versatile and increasingly powerful modality in the evolving landscape of cancer immunotherapy.
References
- Steffin D, et al. Interleukin-15-armoured glypican-3–targeted CAR T cells for advanced solid tumors: a first-in-human clinical study. Nature Medicine. 2025.
doi: 10.1038/s41586-024-08261-8
- Svoboda J, et al. Enhanced CAR T-cell therapy for lymphoma after prior CAR-T failure. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2408771.
- Murad JP, et al. Solid tumour CAR-T cells engineered with IL-12 fusion proteins to enhance efficacy and safety. Nature Biomedical Engineering. 2025. doi: 10.1038/s41551-025-01509-2
Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.
About Marin Biologic Laboratories
Our Recent Publication/Meeting Presentation on Gene Therapy
1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.
3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.
Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise
With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.
Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.
Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories
Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)
Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)
- ADME/Tox
- Molecular Biology
- The Art of Cell Culture
- Exosomes
- Stability Services
- Potency Assay
- Gene Therapy Assays
- Immunotherapy Assays
- Antiviral Therapy Assays
- cGMP
- MLR
- Cell Based Assays
- ELISA
- Flow Cytometry
- Protein
- PCR-qPCR
- Immunoassay
- Radioimmunoassay
- GLP
- Transfection
- Cell Therapy Assays
- Targeted Protein Degradation
- Research to Commercialization
